{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/diagnosis/awaiting-diagnostic-testing/","result":{"pageContext":{"chapter":{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing","depth":2,"htmlHeader":"<!-- begin field 729f1091-ddd4-4da0-acbc-d011b3b77e4e --><h2>How should I manage a person with suspected stable angina who is awaiting diagnostic testing?</h2><!-- end field 729f1091-ddd4-4da0-acbc-d011b3b77e4e -->","summary":"","htmlStringContent":"<!-- begin item e7ca6176-1ecb-4019-bda1-b332845ed1e0 --><!-- begin field 2f6337f9-7631-4777-b477-113f12d07e30 --><ul><li>Follow local protocols for stable angina while waiting for the results of investigations if symptoms are typical of stable angina.</li><li>Provide the person with <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/nitrates/\">sublingual glyceryl trinitrate</a> to use for the relief of symptoms while they are waiting for specialist referral.<ul><li>Instruct the person that if they experience chest pain they should:<ul><li>Stop what they are doing and rest.</li><li>Use their glyceryl trinitrate spray or tablets as instructed.</li><li>Take a second dose after 5 minutes if the pain has not eased.</li><li>Call 999 for an ambulance if the pain has not eased 5 minutes after the second dose, or earlier if the pain is intensifying or the person is unwell.</li></ul></li></ul></li><li>Consider prescribing aspirin (75 mg daily) until the diagnosis is confirmed only if chest pain is considered likely to be stable angina.</li></ul><!-- end field 2f6337f9-7631-4777-b477-113f12d07e30 --><!-- end item e7ca6176-1ecb-4019-bda1-b332845ed1e0 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"77a23b35-11f3-574c-b4c0-818798961d36","slug":"diagnosis","fullItemName":"Diagnosis"},"subChapters":[{"id":"22999896-56e8-545a-8d37-00509ba2a6d0","slug":"basis-for-recommendation-4b0","fullItemName":"Basis for recommendation","depth":3,"htmlHeader":"<!-- begin field 8967c46a-b333-49c0-898d-c9313d2415ee --><h3>Basis for recommendation</h3><!-- end field 8967c46a-b333-49c0-898d-c9313d2415ee -->","summary":null,"htmlStringContent":"<!-- begin item 4b0f3a9f-78df-4dc5-8e0b-a68c90f91364 --><!-- begin field 2b58568a-3d65-4ff9-a03a-3eec29fec43a --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Stable angina: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016b</a>], and <em>Chest pain of recent onset: assessment and diagnosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016a</a>].</p><ul><li>The recommendation to prescribe sublingual glyceryl trinitrate (GTN) is based on the assumption that the working diagnosis of angina is correct, and is considered by CKS to be good clinical practice.</li></ul><h4>Use of sublingual glyceryl trinitrate</h4><ul><li>NICE recommends calling an ambulance if a second dose of GTN does not relieve angina symptoms within 5 minutes. However, the manufacturers of Nitrolingual Pump Spray<sup>®</sup> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016a</a>] and glyceryl trinitrate tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016b</a>] recommend seeking prompt medical attention if symptoms are not relieved after three doses. </li></ul><!-- end field 2b58568a-3d65-4ff9-a03a-3eec29fec43a --><!-- end item 4b0f3a9f-78df-4dc5-8e0b-a68c90f91364 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}